OTCMKTS:MRNA - Marina Biotech Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $22.60 -0.48 (-2.08 %) (As of 05/21/2019 04:49 AM ET)Previous Close$23.08Today's Range$22.55 - $23.6052-Week Range$13.03 - $29.79Volume552,462 shsAverage Volume951,293 shsMarket Capitalization$7.44 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Marina Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension. Its clinical development programs include IT-102 and IT-103, a celecoxib program drug candidates for the treatment of combined arthritis pain/hypertension and the treatment of pain requiring a high dose of celecoxib; CEQ508, an oral delivery of small interfering RNA against beta-catenin, combined with IT-102 to suppress polyps in the precancerous syndrome and orphan indication familial adenomatous polyposis; and CEQ508 combined with IT-103 to treat colorectal cancer. The company is headquartered in City of Industry, California. Receive MRNA News and Ratings via Email Sign-up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:MRNA Previous SymbolOTCMKTS:MRNAD CUSIPN/A CIK737207 Webwww.marinabio.com Phone626-964-5788Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares329,011,000Market Cap$7.44 billion Next Earnings DateN/A OptionableNot Optionable Marina Biotech (OTCMKTS:MRNA) Frequently Asked Questions What is Marina Biotech's stock symbol? Marina Biotech trades on the OTCMKTS under the ticker symbol "MRNA." How were Marina Biotech's earnings last quarter? Marina Biotech, Inc. (OTCMKTS:MRNA) issued its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.01. The biotechnology company had revenue of $16.03 million for the quarter, compared to analyst estimates of $33.59 million. View Marina Biotech's Earnings History. What price target have analysts set for MRNA? 9 Wall Street analysts have issued 12 month target prices for Marina Biotech's stock. Their predictions range from $20.00 to $40.00. On average, they anticipate Marina Biotech's share price to reach $26.7778 in the next year. This suggests a possible upside of 18.5% from the stock's current price. View Analyst Price Targets for Marina Biotech. What is the consensus analysts' recommendation for Marina Biotech? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marina Biotech in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marina Biotech. Has Marina Biotech been receiving favorable news coverage? News stories about MRNA stock have been trending somewhat negative this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Marina Biotech earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. Who are some of Marina Biotech's key competitors? Some companies that are related to Marina Biotech include Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TAK), ASTELLAS PHARMA/ADR (ALPMY), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GNMSF), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Jazz Pharmaceuticals (JAZZ) and Beigene (BGNE). What other stocks do shareholders of Marina Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Marina Biotech investors own include Intelsat (I), Bank of America (BAC), First Data (FDC), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC), Ciena (CIEN), NVIDIA (NVDA) and tronc (TRNC). Who are Marina Biotech's key executives? Marina Biotech's management team includes the folowing people: Mr. Erik Emerson, Chief Commercial Officer & Director (Age 47)Mr. Robert C. Moscato Jr., CEO & Director (Age 42)Mr. Amit Shah, Chief Financial Officer (Age 52)Mr. Mihir Munsif, Chief Operating Officer (Age 55)Dr. Larn Hwang, Chief Scientific Officer (Age 55) When does the company's lock-up period expire? Marina Biotech's lock-up period expires on Wednesday, June 5th. Marina Biotech had issued 26,275,993 shares in its IPO on December 7th. The total size of the offering was $604,347,839 based on an initial share price of $23.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period. Who are Marina Biotech's major shareholders? Marina Biotech's stock is owned by a number of of retail and institutional investors. Top institutional investors include Moloney Securities Asset Management LLC (0.02%), Essex Investment Management Co. LLC (0.01%), Bainco International Investors (0.00%) and Parallel Advisors LLC (0.00%). View Institutional Ownership Trends for Marina Biotech. Which institutional investors are buying Marina Biotech stock? MRNA stock was acquired by a variety of institutional investors in the last quarter, including Moloney Securities Asset Management LLC, Essex Investment Management Co. LLC, Bainco International Investors and Parallel Advisors LLC. View Insider Buying and Selling for Marina Biotech. How do I buy shares of Marina Biotech? Shares of MRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Marina Biotech's stock price today? One share of MRNA stock can currently be purchased for approximately $22.60. How big of a company is Marina Biotech? Marina Biotech has a market capitalization of $7.44 billion. What is Marina Biotech's official website? The official website for Marina Biotech is http://www.marinabio.com. How can I contact Marina Biotech? Marina Biotech's mailing address is 17870 CASTLETON STREET SUITE 250, CITY OF INDUSTRY CA, 91748. The biotechnology company can be reached via phone at 626-964-5788 or via email at [email protected] MarketBeat Community Rating for Marina Biotech (OTCMKTS MRNA)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 112 (Vote Outperform)Underperform Votes: 78 (Vote Underperform)Total Votes: 190MarketBeat's community ratings are surveys of what our community members think about Marina Biotech and other stocks. Vote "Outperform" if you believe MRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Asset Allocation and Your Retirement Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.